When were the Retatrutide trial results released?

Eli Lilly announced late-stage trial results on June 6, 2026, but a commercial launch date has not been set.

How did the Retatrutide results affect LLY stock?

Eli Lilly shares rose 18% in the past month and over 50% in the past year, boosted by the trial results.

Retatrutide Could Extend Eli Lilly’s Weight Loss Market Lead

Eli Lilly announced positive late-stage trial results for its experimental weight-loss drug Retatrutide, driving the stock up 18% in the past month and 50% over the past year.

June 16, 2026

2 min read

Source: Insider Monkey

Key Numbers

stock gain 1m

18%

stock gain 1y

50%

Retatrutide Could Extend Eli Lilly’s Weight Loss Market Lead

Eli Lilly and Co (NYSE:LLY) presented positive late-stage trial results for its experimental obesity drug Retatrutide on June 6, 2026. The announcement comes amid soaring demand for weight-loss treatments, boosting Lilly shares by 18% in the past month and over 50% in the past year.

The Product

Retatrutide is a triple GLP-1/GIP/Glucagon receptor agonist, differentiating it from existing diabetes drugs like Mounjaro. Trials showed significant weight reduction compared to placebo.

Pricing and Availability

Lilly has not yet disclosed pricing or a launch timeline for Retatrutide, but it is expected to be competitively priced against current obesity drugs.

Competition

Retatrutide faces competition from Novo Nordisk’s Wegovy and Lilly’s own Mounjaro. However, its triple mechanism may offer a competitive edge.

Potential Impact on the Company

If approved, Retatrutide could solidify Lilly’s leadership in the rapidly growing weight-loss market, potentially driving substantial revenue growth.

Frequently Asked Questions

Retatrutide is an experimental obesity drug from Eli Lilly that targets GLP-1, GIP, and Glucagon receptors.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.